Effects of tyrosine kinase inhibitor E7080 and eNOS inhibitor L-NIO on colorectal cancer alone and in combination

被引:0
|
作者
Ahmet Altun [1 ]
Tijen Kaya Temiz [1 ]
Ezgi Balc [1 ]
Zübeyde Ak n Polat [2 ]
Mustafa Turan [3 ]
机构
[1] Department of Pharmacology,Cumhuriyet University School of Medicine
[2] Department of General Surgery,Cumhuriyet University School of Medicine
[3] Department of Parasitology,Cumhuriyet University School of Medicine
关键词
E7080; N5-(1-iminoethyl)-L-ornithine dihydrochloride(L-NIO); colorectal cancer; xCELLigence system; tyrosine kinase(TK);
D O I
暂无
中图分类号
R735.3 [肠肿瘤];
学科分类号
100214 ;
摘要
Objective:To investigate the effects of E7080 and N5-(1-iminoethyl)-L-ornithine dihydrochloride(L-NIO)on colorectal cancer alone and in combination.Methods:HT29 colorectal cancer cell line from Sap Institute was used.Real-time cell analysis(xCELLigence system)was performed to determine the effects of E7080 and L-NIO on colorectal cell proliferation.While apoptosis was determined with Annexin V staining,and the effect of agents on angiogenesis was determined with chorioallantoic membrane(CAM)model.Results:We found that E7080 has a strong antiproliferative effect with an half maximum inhibition of concentration(IC50)value of 5.60×10–8mol/L.Also it has been observed that E7080 showed antiangiogenic and apoptotic effects on HT29 colorectal cancer cells.Antiangiogenic scores of E7080 were 1.2,1.0 and 0.6for 100,10 and 1 nmol/L E7080 concentrations,respectively.Furthermore,apoptosis has been detected in71%of HT29 colorectal cancer cells after administration of 100 nmol/L E7080 which may indicate strong apoptotic effect.Meanwhile administration of L-NIO alone did not show any effect,but the combination of E7080 with L-NIO increased the antiproliferative,antiangiogenic and apoptotic effects of E7080.Conclusions:Results of this study indicate that E7080 may be a good choice in treatment of colorectal tumors.Furthermore the increased effects of E7080 when combined with L-NIO raise the possibility to use a lower dose of E7080 and therefore avoid/minimize the side effects observed with E7080.
引用
收藏
页码:572 / 584
页数:13
相关论文
共 50 条
  • [1] Effects of tyrosine kinase inhibitor E7080 and eNOS inhibitor L-NIO on colorectal cancer alone and in combination
    Altun, Ahmet
    Temiz, Tijen Kaya
    Balci, Ezgi
    Polat, Zubeyde Akin
    Turan, Mustafa
    CHINESE JOURNAL OF CANCER RESEARCH, 2013, 25 (05) : 572 - 584
  • [2] Anticancer Effect of COX-2 Inhibitor DuP-697 Alone and in Combination with Tyrosine Kinase Inhibitor (E7080) on Colon Cancer Cell Lines
    Altun, Ahmet
    Turgut, Nergiz Hacer
    Kaya, Tijen Temiz
    ASIAN PACIFIC JOURNAL OF CANCER PREVENTION, 2014, 15 (07) : 3113 - 3121
  • [3] E7080 (Lenvatinib), a Multi-Targeted Tyrosine Kinase Inhibitor, Demonstrates Antitumor Activities Against Colorectal Cancer Xenografts
    Wiegering, Armin
    Korb, Doreen
    Thalheimer, Andreas
    Kaemmerer, Ulrike
    Allmanritter, Jan
    Matthes, Niels
    Linnebacher, Michael
    Schlegel, Nicolas
    Klein, Ingo
    Erguen, Sueleyman
    Germer, Christoph-Thomas
    Otto, Christoph
    NEOPLASIA, 2014, 16 (11): : 972 - 981
  • [4] A Phase II Trial of the Multitargeted Tyrosine Kinase Inhibitor Lenvatinib (E7080) in Advanced Medullary Thyroid Cancer
    Schlumberger, Martin
    Jarzab, Barbara
    Cabanillas, Maria E.
    Robinson, Bruce
    Pacini, Furio
    Ball, Douglas W.
    McCaffrey, Judith
    Newbold, Kate
    Allison, Roger
    Martins, Renato G.
    Licitra, Lisa F.
    Shah, Manisha H.
    Bodenner, Donald
    Elisei, Rossella
    Burmeister, Lynn
    Funahashi, Yasuhiro
    Ren, Min
    O'Brien, James P.
    Sherman, Steven I.
    CLINICAL CANCER RESEARCH, 2016, 22 (01) : 44 - 53
  • [5] A phase I study of E7080, a multitargeted tyrosine kinase inhibitor, in patients with advanced solid tumours
    Boss, D. S.
    Glen, H.
    Beijnen, J. H.
    Keesen, M.
    Morrison, R.
    Tait, B.
    Copalu, W.
    Mazur, A.
    Wanders, J.
    O'Brien, J. P.
    Schellens, J. H. M.
    Evans, T. R. J.
    BRITISH JOURNAL OF CANCER, 2012, 106 (10) : 1598 - 1604
  • [6] Evaluation of management of hypertension in response to the receptor tyrosine kinase inhibitor, E7080: a modeling and simulation approach
    Keizer, R. J.
    Gupta, A.
    Karlsson, M. O.
    Wanders, J.
    Jansen, M.
    Beijnen, J. H.
    Schellens, J. H. M.
    Huitema, A. D. R.
    EJC SUPPLEMENTS, 2010, 8 (07): : 144 - 144
  • [7] E7080, a multi-targeted tyrosine kinase inhibitor suppresses tumor cell migration and invasion
    Glen, Hilary
    Mason, Susan
    Patel, Hitesh
    Macleod, Kenneth
    Brunton, Valerie G.
    BMC CANCER, 2011, 11
  • [8] E7080, a multi-targeted tyrosine kinase inhibitor suppresses tumor cell migration and invasion
    Hilary Glen
    Susan Mason
    Hitesh Patel
    Kenneth Macleod
    Valerie G Brunton
    BMC Cancer, 11
  • [9] A phase I study of E7080, a multitargeted tyrosine kinase inhibitor, in patients with advanced solid tumours
    D S Boss
    H Glen
    J H Beijnen
    M Keesen
    R Morrison
    B Tait
    W Copalu
    A Mazur
    J Wanders
    J P O'Brien
    J H M Schellens
    T R J Evans
    British Journal of Cancer, 2012, 106 : 1598 - 1604
  • [10] Mechanism of antitumor activity of E7080, a selective VEGFR and FGFR tyrosine kinase inhibitor (TKI), in combination with selective mutant BRAF inhibition.
    Matsui, J.
    Narita, Y.
    Semba, T.
    Adachi, Y.
    Kadowaki, T.
    Oestreicher, J.
    Matijevic, M.
    Byrne, M.
    Funahashi, Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)